Shareholders Foundation, Inc.

Quest Diagnostics Incorporated (NYSE:DGX) Shareholder Notice: Investigation over Potential Wrongdoing

An investigation on behalf of investors in Quest Diagnostics Incorporated (NYSE:DGX) shares over potential wrongdoing at Quest Diagnostics Incorporated was announced.


San Diego, CA -- (SBWIRE) -- 05/12/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Quest Diagnostics Incorporated.

Investors who purchased shares of Quest Diagnostics Incorporated (NYSE: DGX) have certain options and should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Quest Diagnostics directors breached their fiduciary duties and caused damage to the company and its shareholders.

Secaucus, NJ based Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. Quest Diagnostics Incorporated reported that its annual Total Revenue rose from over $9.43 billion in 2020 to over $10.78 billion in 2021 and that its Net Income increased from over $1.43 billion in 2020, to over $1.99 billion in 2021.

On January 1, 2022, New York Times released an article regarding the efficacy of Quest Diagnostics Incorporated and other screening labs for certain prenatal tests. The article states that these tests produce misleading results and do not correctly disclose the chances of a false positive. The article elaborates stating, "The test is advertised as getting positive microdeletion results right 75 percent of the time. But that figure comes from a single study that included nine confirmed cases of microdeletions, for a test that screens for seven such disorders. The company doesn't specify how the tests perform individually, and declined to provide that data. (In a statement, Quest said its test has "excellent performance.").

Shares of Quest Diagnostics Incorporated (NYSE: DGX) declined from $174.16 per share on December 31, 2021, to as low as $125.77 per share on February 24, 2022.

Those who purchased shares of Quest Diagnostics Incorporated (NYSE: DGX) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.